Bridging Assay Targets Immunogenicity in Romosozumab and Biosimilar SAL023
A newly developed affinity capture elution bridging assay is aimed at one of the central problems in therapeutic antibody monitoring: detecting anti-drug antibodies with enough sensitivity and specificity to distinguish true immunogenicity from background assay noise. The method was built for romosozumab and its biosimilar SAL023, placing the work squarely in the practical space where assay design, biologic comparability, and patient safety intersect.
For antibody-based therapies, immunogenicity is never a side issue. When the immune system recognizes a biologic as foreign, binding antibodies can complicate exposure, alter pharmacologic activity, and in some settings threaten efficacy or tolerability. A biosimilar program adds another layer of complexity because analytical similarity has to be established across a product pair, and immunogenicity testing must be robust enough to compare them without bias introduced by the assay itself. A well-designed bridging assay is the instrument that makes that comparison credible.
Romosozumab is a monoclonal antibody, and monoclonal antibodies invite the same central analytic challenge across therapeutic classes: the more sensitive the method, the more carefully it must be guarded against interference. Matrix effects, circulating drug, low-level nonspecific binding, and sample handling all have the power to distort the readout. An affinity capture elution bridging assay is designed to reduce some of those problems by enriching the antibody of interest before detection, then using a bridging format to identify antibodies that can bind both capture and detection components. In immunogenicity work, that architecture is attractive because it can improve the chance of detecting clinically relevant antibodies without sacrificing the specificity required for regulatory-grade testing.
The title alone signals an effort that belongs to the translational core of modern immunology: not disease description, but assay architecture. This is where laboratory medicine decides whether a biologic can be followed reliably in development and post-approval evaluation. If the method performs well across both romosozumab and SAL023, it can support head-to-head assessment of antibody responses and help determine whether the biosimilar behaves similarly to the originator with respect to immune recognition.
That matters because biosimilar evaluation is not limited to molecular similarity on paper. The immune system reads subtle structural and formulation differences in ways that are often invisible to standard chemistry alone. Even minor changes in glycosylation, aggregation propensity, impurities, or formulation stress can influence immunogenic risk. A bridging assay gives developers and regulators a way to observe those effects in a controlled analytical framework rather than inferring them from indirect evidence.
The practical bedside consequence is straightforward, even if the work lives in the laboratory. When immunogenicity is assessed with a validated assay, clinicians gain a more trustworthy picture of whether loss of effect, unexpected reactions, or pharmacokinetic drift may be linked to anti-drug antibody formation. In biologic programs, that information shapes labeling, comparability discussions, and the long-term confidence needed for substitution and uptake. In the absence of a dependable assay, the signal can be blurred by false positives, false negatives, or inconsistent drug interference.
Developing a method for both romosozumab and SAL023 also reflects the way biosimilar science is changing. Assay development is no longer limited to proving that a platform works in a single reference product. Comparative immunogenicity testing has become part of the evidentiary structure for biosimilars, and that requires analytical tools that are stable, reproducible, and transferable across related molecules. A bridging assay is especially relevant when the biologic target is clinically important and the immunologic margin for error is narrow.
The assay format itself suggests a focus on real-world laboratory constraints. Affinity capture can improve enrichment from complex samples, and elution steps can concentrate the analyte before bridging detection occurs. That design is useful when circulating drug can mask antibody binding or when antibody concentrations are expected to be low. In therapeutics built on monoclonal antibodies, those details determine whether a test is merely descriptive or actually usable in a development program.
Here, the broader scientific value lies in standardization. A validated assay for romosozumab and SAL023 can serve as a framework for future biologic pairs where immunogenicity must be assessed in parallel. The logic extends beyond one product: build the method carefully, control drug interference, preserve specificity, and create a tool that can support both assay development and comparative immunology.
The paper’s placement in Methods and New Technologies in Immunology fits that agenda precisely. This is not only about detecting antibodies; it is about refining the measurement system that determines how confidently clinicians and regulators can interpret immune responses to biologic therapy. Without that foundation, immunogenicity data remain vulnerable to ambiguity. With it, the field gets a more dependable way to evaluate a reference biologic and its biosimilar counterpart under the same analytical rules.